Stockscreener 앱 받기
1.235
0.40%
-0.005
Standard Biotools Inc 주식(LAB)의 최신 뉴스
Standard BioTools (LAB) Reports Q2 Loss, Tops Revenue Estimates - MSN
Standard Biotools Inc. Faces Challenges in SomaScan Divestiture: Potential Risks and Strategic Imperatives - MSN
Standard BioTools Inc. Stock Lags Behind Sector Benchmarks2025 Price Momentum & Verified Technical Signals - newsimpact.co.kr
Standard Biotools Inc. Faces Divestiture Risks: Management Distraction and Financial Impacts - AInvest
What makes Standard BioTools Inc. stock price move sharply2025 Geopolitical Influence & Weekly Top Gainers Trade List - classian.co.kr
Is Standard BioTools Inc. forming bullish engulfing patternsMarket Weekly Review & Free AI Powered Buy and Sell Recommendations - thegnnews.com
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina - ADVFN Brasil
Standard BioTools Delays Quarterly Report Filing - MSN
Standard BioTools 2025 Q2 Earnings Losses Narrow by 26.8% - AInvest
Casdin funds buys Standard Biotools (LAB) shares worth $443,032 By Investing.com - Investing.com Nigeria
Casdin funds buys Standard Biotools (LAB) shares worth $443,032 - Investing.com
STANDARD BIOTOOLS INC. SEC 10-Q Report - TradingView
Standard BioTools Reports Q2 2025 Financial Results - TipRanks
TD Cowen Downgrades Standard BioTools to Hold From Buy, $1.60 Price Target - MarketScreener
Standard BioTools Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Hold Rating for Standard BioTools Amid Uncertainty Following SomaLogic Sale and Market Challenges - TipRanks
Can Traders Expect Breakout From Standard BioTools Inc. This Week [Sell Signal]Free Weekly Breakout Stock Alerts - 선데이타임즈
Standard BioTools stock holds Sector Weight rating at KeyBanc amid M&A potential - Investing.com Nigeria
KeyBanc Maintains Standard BioTools(LAB.US) With Hold Rating - 富途牛牛
Standard BioTools: Q2 Earnings Snapshot - New Haven Register
Standard BioTools Reports Q2 Loss, Tops Revenue Estimates - AInvest
Standard BioTools Expects FY25 Revenue of $165M-$175M - AInvest
Standard BioTools Steadies Revenue Despite Tough Market Headwinds - Finimize
Standard BioTools Q2 rev. $42mln, SomaLogic sold to Illumina for up to $425mln. - AInvest
Standard BioTools Announces SomaLogic Sale to Illumina - TipRanks
Standard Biotools earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Standard BioTools Q2 revenue dips 3% - MarketScreener
Standard BioTools Reports Second Quarter 2025 Financial Results - The Manila Times
Standard BioTools' Five-Year Share Price Down 84%, Revenue Growth of 3.1% - AInvest
The past five years for Standard BioTools (NASDAQ:LAB) investors has not been profitable - Yahoo Finance
Standard BioTools LAB Q2 2025 Earnings Preview Upside Potential on Strategic Expansion - AInvest
Standard BioTools Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Standard BioTools Q2 2025 Earnings Preview - MSN
Standard BioTools Q2 2025 Earnings Outlook: Strategic Shifts, Revenue Pressures, and the Path to Value Creation - AInvest
What to Expect from Standard BioTools Inc (LAB) Q2 2025 Earnings - Yahoo Finance
Standard BioTools Partners with Precision Health in Singapore for Proteomic Collaboration - AInvest
Standard BioTools and Precision Health Research, Singapore - GlobeNewswire
Major Win: Standard BioTools Secures 100,000-Sample Singapore Biobank Deal for Population Health Study - Stock Titan
Why is Standard BioTools Inc. stock attracting strong analyst attentionUnlock daily stock market insights for success - Jammu Links News
How volatile is Standard BioTools Inc. stock compared to the marketInvest smarter with daily market updates - Jammu Links News
Is Standard BioTools Inc. a growth stock or a value stockBuild wealth with steady, reliable stocks - Jammu Links News
What analysts say about Standard BioTools Inc. stockInvest confidently with data-backed picks - Jammu Links News
How many analysts rate Standard BioTools Inc. as a “Buy”Maximize returns with effective portfolio management - Jammu Links News
What institutional investors are buying Standard BioTools Inc. stockDiscover stocks with explosive potential - Jammu Links News
0.37%
0.50%
자본화:
|
볼륨(24시간):